-
Innovative R&D
-
Tauopathies
-
Sustainable Chemistry
-
Pharmaceutical Research
-
Biotechnology Innovations
-
Alzheimer's Disease
-
Innovative R&D
-
Tauopathies
-
Sustainable Chemistry
-
Pharmaceutical Research
-
Biotechnology Innovations
-
Alzheimer's Disease
Our Mission
At Glyx Therapeutics, we pioneer first-in-class, disease-modifying therapies for tauopathies, including Alzheimer’s disease. Our mission is to translate innovative science into clinically effective treatments, addressing the unmet medical needs of patients worldwide.
- The Science Behind Our Success
- Innovating for a Better Tomorrow
- Beyond Boundaries: Our Scientific Mission
- Driven by Curiosity, Defined by Excellence
- Passion for Science, Commitment to Progress
Our Vision
We aim to redefine the treatment of neurodegenerative diseases by delivering safe, effective, and sustainably produced therapeutics. Our vision is to become a leader in tauopathy care, transforming patient outcomes and quality of life through precision medicine and green chemistry.
-
Targeting tau. Preserving the mind
-
Stopping tau at its root
-
First-in-class science against tau
-
Redefining tau. Rewriting Alzheimer's
-
One protein. Three actions. New hope for the brain
-
Green Chemistry
-
Targeting tau. Preserving the mind
-
Stopping tau at its root
-
First-in-class science against tau
-
Redefining tau. Rewriting Alzheimer's
-
One protein. Three actions. New hope for the brain
-
Green Chemistry
Contact Us
Glyx Therapeutics is committed to advancing the frontier of neurodegenerative disease research through strategic partnerships and collaborations.
We welcome inquiries from members of the scientific community and potential investors who share our dedication to developing first-in-class therapies for tauopathies.
For Research & Scientific Collaboration:
We actively seek partnerships with academic institutions, pharmaceutical company, and fellow biotechnology firms to accelerate the development of our therapeutic pipeline. If your work aligns with our focus on Tau pathology, we invite you to connect with our scientific team to explore potential synergies.
For Investor Relations:
Glyx Therapeutics represents a focused investment opportunity in the expanding neurotherapeutics market. Our lead compound is supported by robust preclinical data and a clear development pathway. For access to our investor deck or to discuss funding opportunities, please direct your inquiry to our corporate development team.
Please use contact details form to ensure your inquiry is directed to the correct department.
We look forward to the possibility of future collaboration.
Glyx Tx Team Will Respond
Our Partners
